Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off

Executive Summary

Withdrawal of filing of CheckMate 227 data in patients with high tumor mutational burden (TMB) means another delay for Opdivo in first-line lung cancer.

You may also be interested in...



Merck's Keytruda Is First Checkpoint Inhibitor To Win US Approval Based On TMB Biomarker

Merck has secured FDA approval for Keytruda for use in tumors with high tumor mutational burden, something Bristol's Opdivo and AstraZeneca's Imfinzi were not able to do in lung cancer.

BMS Ready To Pounce On Non-Chemo Opportunity In Lung Cancer With Checkmate-227 Data

The Checkmate-227 results surprised with an OS benefit for Opdivo plus Yervoy in first-line NSCLC and a miss for the Opdivo-chemotherapy combination. Bristol reported a solid quarter, with growth for IO, Eliquis.

Nektar/Bristol Show Promise With Double IO Combo, But Numbers Are Small

Updated data from PIVOT-02 at the ASCO GU meeting suggest a path for accelerated approval of the NKTR-214/Opdivo combination as first-line treatment of patients with PD-L1-negative urothelial cancers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel